CDK4 and breast carcinoma: To illustrate the use of Dye Drop assays in studying this phenomenon, we exposed hormone receptor positive (HR+) MCF7 cells to three related CDK4/6 inhibitors approved to treat HR+/HER2− breast cancer (palbociclib, ribociclib, and abemaciclib)37,38.